Pioglitazone for diabetes prevention

New England Journal of Medicine

Volumn 365, Issue 2, 2011, Pages 182-184

  McCowen, Karen C ^a   Fajtova, Vera T ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE;

FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79960230999     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1104572     Document Type: Letter

References (4)

1. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-15.
2. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-80.
3. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-6. (Pubitemid 40446330)
4. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803. (Pubitemid 34970933)